



## PRESS RELEASE

January 23, 2023

# Ziccum submits Expression of Interest for CEPI funding

**Ziccum AB (publ) ('Ziccum') has now submitted its Expression of Interest application for CEPI's Call for Proposals for funding of innovations that improve vaccine thermostability.**

The Coalition for Epidemic Preparedness (CEPI), in 2022 invited players developing innovative technologies to improve vaccine thermostability to apply for a funding opportunity.

After initially communicating that it would not submit a proposal, due to not having a relevant partner, Ziccum was subsequently approached by a well-established biotech company within mRNA vaccine technology, and the application was reopened.

Ziccum has now submitted the Expression of Interest (EoI), where the deadline is 31 January 2023. In the next stage of the grant application process, selected applicants will be invited by CEPI to develop a more elaborate and detailed grant application. The precise timeline for this has not been made official by CEPI.

Ziccum Project leader, Louise Egeblad: "We are pleased to have completed our application for this initial Expression of Interest-step, and we are happy to have a fruitful partner dialogue running."

**About CEPI:** CEPI, the Coalition for Epidemic Preparedness Innovations, funds a wide range of research projects to develop vaccines through donations from public, private, charitable and civil society organizations. CEPI is headquartered in Oslo, Norway. [Read CEPI's Call for Proposals.](#)

**For more information about Ziccum, please contact:**

---

Ann Gidner,  
CEO Ziccum  
Mail: gidner@ziccum.com  
Mobile: +46 722140141

Fredrik Sjövall,  
Chairman of the Board, Ziccum AB  
Mail: sjovall@ziccum.com  
Mobile: +46 706 45 08 75

Ziccum's Certified Adviser is Erik Penser Bank AB

## About Ziccum

---

Ziccum is developing LaminarPace™, a unique ambient drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry. By reducing drying stress to the active ingredient, LaminarPace™ uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes. The technology has been successfully applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application. Ziccum is listed on the Nasdaq First North Growth Market.

## Attachments

---

[Ziccum submits Expression of Interest for CEPI funding](#)